Literature DB >> 7527664

In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells.

F C Zeigler1, F de Sauvage, H R Widmer, G A Keller, C Donahue, R D Schreiber, B Malloy, P Hass, D Eaton, W Matthews.   

Abstract

Recently, the ligand for c-mpl has been identified and cloned. Initial studies of this molecule indicate that it is the platelet regulatory factor, thrombopoietin (TPO). Previous work has indicated that c-mpl is expressed in very immature hematopoietic precursors and thus raised the possibility that TPO may act directly on the hematopoietic stem cell. Therefore, in these studies, we investigate the effects of TPO on hematopoietic stem cell populations isolated from the murine fetal liver and bone marrow. Cocultivation of stem cells with fetal liver stroma give rise to multilineage expansion of the stem cells but with little or no megakaryocytopoiesis. Addition of TPO to these cocultures gives significant megakaryocyte production. This production is enhanced in combination with Kit ligand or interleukin-3. The addition of TPO to stem cell suspension cultures produces a dynamic thrombopoietic system in which stem cells undergo differentiation to produce megakaryocytes and proplatelets. These experiments show that the megakaryocytopoietic and thrombopoietic activities of TPO are initiated at the level of an early progenitor cell or upon the hematopoietic stem cell.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527664

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

Review 1.  Primary thrombocytosis in children.

Authors:  Nicole Kucine; Katherine M Chastain; Michelle B Mahler; James B Bussel
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

2.  Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.

Authors:  Ronan Desmond; Danielle M Townsley; Bogdan Dumitriu; Matthew J Olnes; Phillip Scheinberg; Margaret Bevans; Ankur R Parikh; Kinneret Broder; Katherine R Calvo; Colin O Wu; Neal S Young; Cynthia E Dunbar
Journal:  Blood       Date:  2013-12-17       Impact factor: 22.113

Review 3.  Nontransplant therapy for bone marrow failure.

Authors:  Danielle M Townsley; Thomas Winkler
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

4.  Role of the distal half of the c-Mpl intracellular domain in control of platelet production by thrombopoietin in vivo.

Authors:  S M Luoh; E Stefanich; G Solar; H Steinmetz; T Lipari; T I Pestina; C W Jackson; F J de Sauvage
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

Review 5.  Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia.

Authors:  Andrea Bacigalupo; Sabrina Giammarco; Simona Sica
Journal:  Int J Hematol       Date:  2016-06-08       Impact factor: 2.490

6.  Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells.

Authors:  Jose Perdomo; Feng Yan; Halina H L Leung; Beng H Chong
Journal:  J Vis Exp       Date:  2017-12-27       Impact factor: 1.355

7.  Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia.

Authors:  A M Farese; P Hunt; L B Grab; T J MacVittie
Journal:  J Clin Invest       Date:  1996-05-01       Impact factor: 14.808

Review 8.  Eltrombopag: Role in Cytopenias Following Hematopoietic Stem Cell Transplantation.

Authors:  Ram Vasudevan Nampoothiri; Rajat Kumar
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-24       Impact factor: 0.900

Review 9.  From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag.

Authors:  Harinder Gill; Raymond S M Wong; Yok-Lam Kwong
Journal:  Ther Adv Hematol       Date:  2017-02-01

Review 10.  The optimal immunosuppressive therapy for aplastic anemia.

Authors:  Seung Hwan Shin; Jong Wook Lee
Journal:  Int J Hematol       Date:  2013-04-19       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.